# Amira Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amira-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.amirapharm.com
- Total disclosed funding: $25M
- Latest round: Series B (Feb 16, 2007)
- Investors on record: 4

## About

Amira Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies and healthcare solutions to address various medical needs and enhance patient outcomes.Amira Pharmaceuticals, founded in 2005, is based in San Diego, US. The company specializes in biopharmaceuticals, focusing on the development of novel therapies. In September 2011, Amira was acquired by Bristol-Myers Squibb Company for USD 325 mn. The company has participated in 2 investment deals, with the most recent transaction occurring in 2011.Amira Pharmaceuticals specializes in providing a range of pharmaceutical products and services designed to address various healthcare needs. The company's core offerings include a selection of prescription medications, over-the-counter solutions, and specialized health supplements. These products are developed through rigorous research and innovative formulations aimed at improving patient outcomes and enhancing overall quality of life. Amira primarily serves healthcare providers, pharmacies, and end-users, focusing on markets in North America, Europe, and select regions in Asia, and is known for delivering high-quality products that meet stringent regulatory standards.Amira Pharmaceuticals generates revenue through a structured transaction model that includes direct sales to healthcare providers and partnerships with wholesalers and retailers. The company engages in B2B transactions, supplying pharmacies and healthcare institutions, thereby ensuring broad distribution of its pharmaceutical offerings. Revenue is derived from sales of individual products, including flagship products recognized for their efficacy and safety in addressing specific health issues. Pricing structures are determined based on market conditions and competitive analysis, allowing Amira to maintain its market position while ensuring affordability for end-users.Amira Pharmaceuticals currently has strategies in place for future growth, which includes the development of new products aimed at addressing specific healthcare challenges. The company is also planning to expand into new markets, specifically targeting regions in Asia by the end of 2023. The recent acquisition by Bristol-Myers Squibb will support these initiatives, enabling the company to leverage resources for product development and market expansion.

## Funding rounds

- Series B, Feb 16, 2007, $25M — Prospect Venture Partners, Versant Ventures, Avalon Ventures, Novo Holdings

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series B
- Novo Holdings — Series B